Shares lost a quarter of their value after the company disclosed, in a regulatory filing, signs of liver stress in a study ...

A therapy at the center of their $22 billion alliance failed to extend survival in a type of lung tumor, leading the ...

The funding was meant to help the U.S. prepare for pandemics triggered by avian flu strains, but now leaves the future of ...

After a three-year drought, the industry is questioning whether the window for medtech public offerings is open following a ...